



## Executive summary of Joint Working Inputs

Cardiology, Renal & Diabetology – Linking Expertise (CRAD-LE)

Published on [Working with the NHS \(astrazeneca.co.uk\)](https://astrazeneca.co.uk)

<b>Project title</b>	<i>Cardiology, Renal &amp; Diabetology – Linking Expertise (CRAD-LE)</i>
<b>Duration</b>	1 <sup>st</sup> March 2022 and ending on 28 <sup>th</sup> February 2023
<b>Project partners</b>	<i>NHS Greater Glasgow and Clyde (NHSGGC) and AstraZeneca</i>
<b>What was the issue to be addressed?</b>	<p>The project aims and objectives were to improve cardiovascular &amp; renal outcomes for patients with Type 2 Diabetes, Type 2 Diabetes &amp; Heart Failure with a Reduced Ejection Fraction &amp; Type 2 Diabetes and Chronic Kidney Disease by establishing a novel service to provide diabetes support to cardiology, nephrology, and primary care, focussing initially on secondary care in GGC, to ensure optimal initiation of guideline recommended treatments for patients with Type 2 Diabetes and Heart Failure with a Reduced Ejection Fraction and/or Chronic Kidney Disease stage 3.</p> <p>The objectives were to:</p> <ol style="list-style-type: none"><li>1) accelerate medicines optimisation with cardio-renal protective agents in secondary care and primary care</li><li>(2) provide educational support via patients case studies that increase HCP confidence in managing patients' Cardio-Renal risk factors</li></ol>

GB-47897 DOP: 17-08-2023